<DOC>
	<DOCNO>NCT01523678</DOCNO>
	<brief_summary>Rationale : The administration prophylactic G-CSF may reduce toxicity weekly paclitaxel/carboplatin regimen gynaecological cancer . Purpose : This multicenter phase II trial study side effect weekly paclitaxel/carboplatin give prophylactic G-SCF patient recurrent epithelial ovarian- , primary peritoneal fallopian tube cancer , endometrial carcinoma cervical carcinoma . Data obtain trial compare historical data publish earlier . The trial include 3 cohort 36 patient : - Subjects ovarian , fallopian tube peritoneal carcinoma - Subjects endometrial cancer - Subjects cervical carcinoma Treatment : Subjects receive Paclitaxel 60 mg/mÂ² follow Carboplatin AUC 2.7 intravenously weekly 18 week . Filgrastim ( Neupogen ) give patient day 5 possibly day 6 course . Subjects evaluate CT/MRI scan 9 cycle chemotherapy ( week 10 ) , 18 cycle chemotherapy , every 6 month next 2 year clinically indicate . Subjects develop disease progression discontinue therapy . Subjects evidence disease progression completion study therapy follow disease progression , withdrawal informed consent , death .</brief_summary>
	<brief_title>Weekly Paclitaxel/Carboplatin With Neupogen Gynaecological Cancers</brief_title>
	<detailed_description>Primary objective : - To evaluate occurrence grade 4 neutropenia weekly paclitaxel/carboplatin prophylactic G-CSF Secondary objective : - To evaluate per cohort occurrence grade 4 neutropenia - To evaluate toxicity - To evaluate dose reduction dose delay chemotherapy - To determine progression free survival accord RECIST v1.1 - To evaluate response rate overall survival</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All cohort : Female subject 18 year age Performance status must ECOG 02 . Adequate organ function Measurable disease RECIST version 1.1 CA125 progression accord GCIG definition ( Vergote et al ) . Written inform consent Ovarian , fallopian tube peritoneal carcinoma cohort : Histologically confirm diagnosis invasive epithelial ovarian , fallopian tube , peritoneal carcinoma ( serous , mucinous , endometrioid , clear cell , carcinosarcomas eligible ) . Patients receive least 1 early platin treatment platin refractory ( progression within 28 day last dose platin ) platin resistant ( progression within 6 month last dose platin therapy ) . Earlier weekly dosedense regimens paclitaxel carboplatin allow . Consolidation last platin dose nonplatinum contain chemotherapy molecular target drug allow Endometrial carcinoma cohort Histologically confirm diagnosis endometrial carcinoma ( endometrioid , adenoacanthoma , adenosquamous , serous , clear cell carcinoma carcinosarcoma eligible ) . Recurrent advance endometrial carcinoma include . Earlier platin therapy allow . But earlier weekly dosedense regimens paclitaxel carboplatin allow . Cervical carcinoma cohort Histologically confirm diagnosis cervical carcinoma ( adenocarcinoma squamous carcinoma eligible ) . Recurrent advance endometrial carcinoma include . Earlier platin ( include concomitant radiotherapy ) therapy allow . But earlier weekly dosedense regimens paclitaxel carboplatin allow . Other histology mention nonepithelial ovarian carcinoma , neuroendocrine tumor , sarcoma , metastases primary tumor , ... Earlier weekly dosedense paclitaxel carboplatin regimen . Any unstable serious condition e.g . uncontrolled infection require systemic therapy . Prior malignancy treat primarily recurrence within 3 year prior inclusion study , except completely resect non melanomatous skin carcinoma successfully treat situ carcinoma skin cervix uterus . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedures Metastatic disease brain leptomeninges . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 14 day prior first dose study chemotherapy . chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose study drug Known immediate delay hypersensitivity reaction idiosyncrasy drug similar related Paclitaxel , Carboplatin GCSF .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Endometrial Carcinoma</keyword>
	<keyword>Uterine Cervical Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Ovarian Diseases</keyword>
	<keyword>Peritoneal Diseases</keyword>
	<keyword>Fallopian Tube Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Endometrial Diseases</keyword>
	<keyword>Uterine Cervical Diseases</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Peritoneal Neoplasms</keyword>
	<keyword>Fallopian Tube Neoplasms</keyword>
	<keyword>Neoplasms , Endometrial</keyword>
	<keyword>Cervical Neoplasms</keyword>
	<keyword>Genital Neoplasms , Female</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
	<keyword>Genital Diseases , Female</keyword>
</DOC>